为了迅速取得吡喹酮治疗人体3种血吸虫病的初步临床药理学研究资料,世界卫生组织和西德拜耳药厂进行了协作,分别在巴西、日本、菲律宾和赞比亚开展了该药耐受性的双盲试验和/或抗虫效果的单盲试验,研究结果已分别报告。由于在不同地区的多中心实验中采取了由协作双方共同商定的实验设计和实施方案,因此在研究过程中出现的问题比预期的要少,且能较迅速的完成初步的临床药理研究计划。作者认为这种协作对于 In order to rapidly obtain preliminary clinical pharmacological research data on the treatment of three human schistosomiasis patients with praziquantel, WHO and West Bayer Pharmaceuticals collaborated to conduct the drug-tolerant study in Brazil, Japan, the Philippines and Zambia Double-blind and / or single-blind experiments with insect resistance results have been reported separately. Due to the experimental design and implementation protocols mutually agreed upon by the collaborating parties in multi-center experiments in different regions, fewer problems than expected were anticipated during the study and the preliminary clinical pharmacology research plan could be completed more rapidly. The authors consider this collaboration to be